All In Biotech

Drug Trial Radar · NCT05439824

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

A Randomized, Observer-blinded, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Immunogenicity and Safety of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Healthy Participants Aged 18 Years or More

Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

450

Actual

Start

Jun 28, 2022

Primary completion

Jan 12, 2023

Study completion Jun 28, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006)in healthy participants aged 18 or more.

Conditions

  • SARS-CoV-2 Infection

Interventions

  • SYS6006 20 μgBiological

    SARS-CoV-2 mRNA Vaccine

  • SYS6006 30 μgBiological

    SARS-CoV-2 mRNA Vaccine

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibodyTime frame: 14 days after the second dose
  2. Adverse events (AEs), including solicited AEs and unsolicited AEsTime frame: From the first dose through 30 days following the second dose
  3. AEs associated with the study interventionTime frame: From the first dose through 30 days following the second dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hebei Provincial Center For Disease Control and Prevention

    Shijiazhuang, Hebei, China

  • Sir Run Run Hosipital Nanjing Medical University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.